Sarah L. Wicks

Déjà Vu: OPDP Again Targets Provider Branded Website Of Accelerated Approval Drug In Second Untitled Letter Of 2025

More On The Impact Of The FDA RIFs: How Information Disclosure Will Start FOIA-lling Behind

Regulator And Funder? FDA's Orphan Products Grants Program Awards Significant Funding To Help Move Promising Treatments Through Clinical Development